Stock Track | Immunocore Holdings Plummets 5.02% Intraday After Q4 Earnings Miss and Moderating 2026 Growth Outlook

Stock Track

Feb 26

Immunocore Holdings plc (IMCR) saw its shares plummet 5.02% during intraday trading on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results.

The biotechnology company reported a quarterly adjusted loss of $0.60 per share, which was significantly wider than the analyst consensus estimate for a loss of $0.24 per share. Revenue for the quarter came in at $104.48 million, also missing expectations of $107.31 million. Furthermore, the company indicated it expects moderating revenue growth in 2026, contributing to negative investor sentiment.

The earnings miss on both the top and bottom lines, combined with a cautious outlook for the coming year, appears to be the primary driver behind the stock's significant intraday decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1186423895"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186423895\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186423895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186423895","market":"sg","top_or_hot":-1,"title":"Stock Track | Immunocore Holdings Plummets 5.02% Intraday After Q4 Earnings Miss and Moderating 2026 Growth Outlook","media":"Stock Track","content":"<p>Immunocore Holdings plc (IMCR) saw its shares plummet 5.02% during intraday trading on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The biotechnology company reported a quarterly adjusted loss of $0.60 per share, which was significantly wider than the analyst consensus estimate for a loss of $0.24 per share. Revenue for the quarter came in at $104.48 million, also missing expectations of $107.31 million. Furthermore, the company indicated it expects moderating revenue growth in 2026, contributing to negative investor sentiment.</p><p>The earnings miss on both the top and bottom lines, combined with a cautious outlook for the coming year, appears to be the primary driver behind the stock's significant intraday decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immunocore Holdings Plummets 5.02% Intraday After Q4 Earnings Miss and Moderating 2026 Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immunocore Holdings Plummets 5.02% Intraday After Q4 Earnings Miss and Moderating 2026 Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 04:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immunocore Holdings plc (IMCR) saw its shares plummet 5.02% during intraday trading on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The biotechnology company reported a quarterly adjusted loss of $0.60 per share, which was significantly wider than the analyst consensus estimate for a loss of $0.24 per share. Revenue for the quarter came in at $104.48 million, also missing expectations of $107.31 million. Furthermore, the company indicated it expects moderating revenue growth in 2026, contributing to negative investor sentiment.</p><p>The earnings miss on both the top and bottom lines, combined with a cautious outlook for the coming year, appears to be the primary driver behind the stock's significant intraday decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMCR","symbol_name":"Immunocore Holdings plc","start_time":0,"source_url":"","article_id":"1186423895","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186423895","pubTimestamp":1772050119,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immunocore Holdings plc (IMCR) saw its shares plummet 5.02% during intraday trading on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMCR":"Immunocore Holdings plc"},"translate_title":"个股追踪|第四季度盈利未达预期且2026年增长前景放缓后，Immunocore Holdings盘中暴跌5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMCR":1},"content_text":"Immunocore Holdings plc (IMCR) saw its shares plummet 5.02% during intraday trading on Wednesday. The sharp decline followed the release of the company's fourth-quarter and full-year 2025 financial results.The biotechnology company reported a quarterly adjusted loss of $0.60 per share, which was significantly wider than the analyst consensus estimate for a loss of $0.24 per share. Revenue for the quarter came in at $104.48 million, also missing expectations of $107.31 million. Furthermore, the company indicated it expects moderating revenue growth in 2026, contributing to negative investor sentiment.The earnings miss on both the top and bottom lines, combined with a cautious outlook for the coming year, appears to be the primary driver behind the stock's significant intraday decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}